Your browser is not up to date and is not able to run this publication.
Learn more

Conclusions

These data suggest that Simeox therapy alone or combined with chest physiotherapy is safe and feasible in adult CF with good

tolerability for most of patients.

Simeox therapy may provide additional benefits on lung clearance in term of comfort and perceived efficiency.

Results

11 adult CF patients were included in the subgroup analysis. Mean age was 34±9 years, 7 male and 4 women, BMI 19.8±3.2. Mean rate of usual chest physiotherapy session was 31±16/month. Baseline PFTs: FEV1 1015±401 ml, FVC 1919±641 ml, FEV1% 31±13%, FEV1/FVC% 52±6%,

Median duration of sessions was similar (30 min) between Simeox and usual chest physiotherapy. All patients completed the

study. No side effect nor decrease of SpO2 was reported during both interventions. There was no significant difference in SpO2

change between Simeox and usual chest physiotherapy alone (morning session with/without Simeox) or between combined

ACTs and usual physiotherapy alone (days with/without Simeox).

Daily secretion clearance was significantly improved with combined ACTs (median [Q1-Q3]: 38 [19-48] vs 26 [17-38]g, p=0.025)

compared to usual chest physiotherapy alone.

No patient discontinued device therapy. Simeox therapy was not painful in 9 patients. 2 patients reported moderate pain and 2

patients experienced very tiring sessions with Simeox compared to usual chest physiotherapy.

After the second Simeox session, 9 patients were satisfied with device therapy and 7 patients preferred use of Simeox alone or

combined therapy rather than usual chest physiotherapy alone.

VISIT 0

VISIT 1

VISIT 2

VISIT 3

VISIT 4

VISIT 5

INCLUSION VISIT

4 RESPIRATORY THERAPIST (RT) VISITS: TWICE DAILY SESSION

MORNING AFTERNOON

USUAL ACT USUAL ACT

SIMEOX USUAL ACT

USUAL ACT USUAL ACT

SIMEOX USUAL ACT

END OF STUDY

7